GPhA Announces 2014 Board of Directors

Published Online: Wednesday, February 19, 2014
Follow Pharmacy_Times:

(ORLANDO, FL and WASHINGTON, DC, February 19, 2014) — The Generic Pharmaceutical Association (GPhA) today announced the election of its 2014 Executive Committee and Board of Directors.

Craig Wheeler, President and CEO, Momenta Pharmaceuticals, was elected as GPhA Board Chairman. Wheeler succeeds Tony Mauro, President, Mylan North America.

“I’m honored to be elected as chairman of GPhA’s Board of Directors,” said Wheeler. “Our member companies provide timely access to safe and affordable generic medicines for patients around the globe, putting treatment within reach for hundreds of millions of people. There are so many opportunities ahead for this dynamic industry, and I look forward to contributing to our shared success.”

Generic medicines have saved the U.S. system $1.2 trillion over the past decade and $217 billion in 2012 alone, according to the 2013 Generic Drug Savings in the U.S. report, conducted by IMS Institute for Healthcare Informatics on behalf of GPhA.

“It is a time of extraordinary promise for our industry,” said Ralph G. Neas, President and CEO of GPhA. “Patient safety remains our top priority as the Association leads efforts to preserve and promote access to generic medicines. Chairman Wheeler’s strong leadership will be pivotal as the industry works with the FDA, Congress and stakeholders at all levels of the health care system to improve labeling guidance, establish a framework for interchangeable biologic substitution, meet GDUFA goals, and advocate for policies that encourage generic utilization at home and abroad.”

The 2014-2015 GPhA Board of Directors will be:
  • Carole Ben-Maimon (Impax Laboratories)
  • Doug Boothe (Perrigo Company)
  • Chuck Caprariello (Ranbaxy, Inc.)
  • John Ducker (Fresenius Kabi)
  • Jeff Glazer (Heritage Pharmaceuticals)
  • Peter Goldschmidt (Sandoz US)
  • Tony Mauro (Mylan Inc.)
  • Thomas Moore (Hospira Inc.)
  • Allan Oberman (Teva Americas)
  • Chirag Patel (Amneal Pharmaceuticals)
  • Joseph Renner (Zydus Pharmaceuticals, Inc.)
  • Jeff Watson (Apotex Corporation)
  • Craig Wheeler (Momenta Pharmaceuticals)
  • Paul McGarty (Lupin Pharmaceuticals) (at-large director)
Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues